Jubilant Pharmova Ltd on Tuesday released its fiscal first quarter earnings report with a sharp profit decline of 78.66 per cent on year on a high base from last year and due to an improvement in operating performance and reduced finance cost. Profit for the quarter stood at Rs 102.90 crore in comparison to Rs 482.10 crore reported during the corresponding quarter of FY25. The Q1FY25 profit at Rs 482.10 crore was higher because of one time net exceptional income of Rs 396 crore.
Even so, the pharma company recorded revenue from operations at Rs 1,900.70 crore, posting a growth of 9.76 per cent YoY on the back of growth in revenue across all business units. EBITDA, meanwhile, grew by 14 per cent on a YoY basis to Rs 302 crore due to improved performance in CRDMO and Generics.
Jubilant Pharma Q1 performance across business verticals
Radiopharmaceuticals Q1FY26 revenue went up by 3 per cent to Rs 271 crore and EBITDA remained stable on-year at Rs 126 crore.
Radiopharmacy Q1FY26 revenue grew by 5 per cent YoY to Rs 598 crore. EBITDA margins for the quarter in review stood at 2 per cent. EBITDA margins remained weak due to increased competitive intensity in the SPECT business. “Jubilant Pharmova’s radiopharmacy network is the second largest in the US and shall drive the future business growth,” it said.
In Q1FY26, Allergy Immunotherapy business posted revenue growth of 8 per cent to Rs 181 crore on the back of growth in revenues from the US market. EBITDA remained stable YoY at Rs 63 crore.
CDMO Sterile Injectables recorded Q1 revenue growth of 14 per cent to Rs 370 crore due to increase in sales volume. EBITDA grew by 9 per cent to Rs 62 crore.
In the CRDMO segment, drug discovery revenue grew by 42 per cent to Rs 161 crore and EBITDA went up by 46 per cent to Rs 32 crore. The revenue growth was attributed to increase in revenue from large pharma customers. EBITDA margins were lower QoQ due to change in project mix and investment in business development. The API business revenue grew by 9 per cent to Rs 141 crore in Q1FY26 and EBITDA went up by 36 per cent to Rs 22 crore.
The Generics business posted revenue growth of 7 per cent to Rs 166 crore. EBITDA for the period came in at Rs 12 crore. Revenue growth, it added, was primarily driven by non-US markets.
Shyam S Bhartia, Chairman, Jubilant Pharmova and Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova, said, “As we are consciously investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, net debt/ EBITDA increased marginally from 1.1x in Mar’25 to 1.2x in Jun’25 on the back of increased capex intensity.
Jubilant Pharma grants stock options to employees
The Board of Directors at Jubilant Pharmova also approved the grant of 1,21,560 Stock Options/Restricted Stock Units (RSUs) to select eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.
The stock options were offered at an exercise price of Re 1 per equity share, reflecting the face value of the company’s shares.
Shares of Jubilant Pharmova dropped by 1.35 per cent at 3:50 pm to a trading price of Rs 1,157.95.